NeuroSense Therapeutics Ltd. (NRSNW) Stock Ticker
NRSNW right now
Market factors today
Unlock the full NRSNW picture
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.
NRSNW stock facts
| Ticker symbol | NRSNW |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $989,133 |
| CEO | Alon Ben-Noon |
| Employees | 16 |
| Headquarters | Herzliya, TA, IL |
| IPO date | 2021-12-09 |
| Website | www.neurosense-tx.com |
What you can see for NRSNW on Tickr
Live NRSNW price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the NRSNW report.
Rankings
FAQ
What is the ticker symbol for NeuroSense Therapeutics Ltd.?
The ticker symbol for NeuroSense Therapeutics Ltd. is NRSNW, listed on the NASDAQ Capital Market.
What is NRSNW?
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC,…